Kenvue CEO Discusses Growth Outlook After J&J Unit Jumps 20% in Market Debut

Johnson & Johnson's consumer-health unit Kenvue made its debut on the New York Stock Exchange and jumped about 20% on Thursday. Thibaut Mongon, CEO of Kenvue, joined Cheddar News to discuss business growth goals and what lies ahead for its well-known pipeline of products, including Band-Aid, Neutrogena, Tylenol, among others.

More In Business

FDA takes aim at Hims & Hers, weight loss drugs in new advertising blitz

The Trump administration has issued its first warnings to online services that offer unofficial versions of popular drugs like the blockbuster obesity treatment Wegovy.

McDonald’s will invest $200 million in regenerative cattle ranches

McDonald’s said Monday it plans to invest $200 million over the next seven years to promote regenerative agriculture practices on cattle ranches.

How much for matcha? Prices for the popular powdered tea soar

The world’s fondness for matcha is about to be tested by steep price increases.

The Fabric of Success: BrilliA’s CEO on Innovation, IPO, and Market Leadership

Kendrew Hartanto, CEO of BrilliA (NYSE: BRIA), shares how the company stitched its path to IPO and redefined leadership in women’s undergarments.

Big Business This Week: Oracle soars as it cashes in on the AI boom

Oracle soars as it cashes in on the AI boom, Plus: Starbucks shares continue to fall under its new CEO, and does anybody actually want a new iPhone Air?

Why are Marvel movies losing more money, lately?

Ever since Disney paid $4 billion for the Marvel franchise in 2009, their movies have been making less and less money. What’s going on?

Load More